PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates ...

The FDA has approved Ketarx, a ketamine-based drug developed by drugmaker PharmaTher, for use in pain management. The medication is now cleared by the FDA for clinical use in perioperative settings, ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company ...

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical ...

PharmaTher Holdings Ltd ( ($TSE:PHRM) ) just unveiled an update. PharmaTher Holdings Ltd. has received FDA approval for its ketamine product, ...

The psychedelic pharmaceutical sector continues gaining mainstream acceptance as regulatory barriers fall and medical ...

PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine Jul. 02, 2025 8:00 AM ET PharmaTher Holdings Ltd ...

"PharmaTher is committed to revolutionizing patient care through ketamine. With KetaVault™, PharmaTher isn't just sharing data; we're igniting a new era of collaborative ketamine innovation.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...